To expand the safety and tolerability profile for the administration of [18F]APN-1607 and PET scanning.~To assess regional patterns of [18F]APN-1607 uptake.~To evaluate the relationship between regional measures of [18F]APN-1607 uptake and measurements of AD disease severity, such as National Institute on Aging and Alzheimer's Association (NIA-AA) diagnosis, Mini-mental Status Exam (MMSE) score, and Alzheimer's Disease Assessment Scale-cognitive subscale (ADAScog).
The overall objective of this study is to evaluate the overall pattern of [18F]APN-1607 uptake in subjects with AD dementia